KR950016734A - 성적 조숙증의 억제방법 - Google Patents

성적 조숙증의 억제방법 Download PDF

Info

Publication number
KR950016734A
KR950016734A KR1019940034925A KR19940034925A KR950016734A KR 950016734 A KR950016734 A KR 950016734A KR 1019940034925 A KR1019940034925 A KR 1019940034925A KR 19940034925 A KR19940034925 A KR 19940034925A KR 950016734 A KR950016734 A KR 950016734A
Authority
KR
South Korea
Prior art keywords
compound
inhibition
formula
administration
pyrrolidino
Prior art date
Application number
KR1019940034925A
Other languages
English (en)
Inventor
알란 듀지 제프리
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950016734A publication Critical patent/KR950016734A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

효과량의 하기 일반식( I )의 화합물, 또는 그의 약학적으로 허용가능한 염 또는 용매화물을 성적 조숙증의 억제를 필요로 하는 인간에게 투여함을 포함하여 이루어지는, 상기 질환의 억제방법:
상기식에서,
Rl및 R3는 독립적으로 수소,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노, 헥사메틸렌이미노 및 피페리디노로 이루어진 그룹중에서 선택된다.

Description

성적 조숙증의 억제방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 성적 조숙증의 억제에 사용하기 위한 하기 일반식( I )의 화합물, 또는 그의 약학적으로 허용가능한 염 또는 용매화물:
    상기식에서,
    R1및 R3는 독립적으로 수소, -CH3,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노 및 피페리디노로 이루어진 그룹중에서 선택된다.
  2. 제1항에 있어서, 상기 화합물이 그의 염산 염인 화합물:
  3. 제1항에 있어서, 상기 투여가 예방약으로서의 투여인 화합물.
  4. 제1항에 있어서, 상기 화합물이 하기 구조식의 화합물 또는 그의 염산 염인 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940034925A 1993-12-21 1994-12-19 성적 조숙증의 억제방법 KR950016734A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/171,393 1993-12-21
US08/171,393 US5451590A (en) 1993-12-21 1993-12-21 Methods of inhibiting sexual precocity

Publications (1)

Publication Number Publication Date
KR950016734A true KR950016734A (ko) 1995-07-20

Family

ID=22623576

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940034925A KR950016734A (ko) 1993-12-21 1994-12-19 성적 조숙증의 억제방법

Country Status (14)

Country Link
US (2) US5451590A (ko)
EP (1) EP0659420A1 (ko)
JP (1) JPH07215857A (ko)
KR (1) KR950016734A (ko)
CN (1) CN1108099A (ko)
AU (1) AU8155294A (ko)
CA (1) CA2138507A1 (ko)
CZ (1) CZ321794A3 (ko)
HU (1) HUT71340A (ko)
IL (1) IL112051A0 (ko)
NO (1) NO944931L (ko)
NZ (1) NZ270179A (ko)
RU (1) RU94045156A (ko)
ZA (1) ZA9410075B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
ATE406909T1 (de) 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US7209221B2 (en) * 1994-05-23 2007-04-24 Automotive Technologies International, Inc. Method for obtaining and displaying information about objects in a vehicular blind spot
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
PT1175433E (pt) 1999-05-04 2005-11-30 Strakan Int Ltd Glicosidos androgenos e sua actividade androgenica
US7852462B2 (en) * 2000-05-08 2010-12-14 Automotive Technologies International, Inc. Vehicular component control methods based on blind spot monitoring

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (ko) * 1962-09-13
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
IL112051A0 (en) 1995-03-15
EP0659420A1 (en) 1995-06-28
CA2138507A1 (en) 1995-06-22
CZ321794A3 (en) 1995-09-13
US5552417A (en) 1996-09-03
NZ270179A (en) 1996-08-27
RU94045156A (ru) 1996-10-20
HUT71340A (en) 1995-11-28
AU8155294A (en) 1995-06-29
JPH07215857A (ja) 1995-08-15
HU9403669D0 (en) 1995-02-28
ZA9410075B (en) 1996-06-19
CN1108099A (zh) 1995-09-13
NO944931D0 (no) 1994-12-19
NO944931L (no) 1995-06-22
US5451590A (en) 1995-09-19

Similar Documents

Publication Publication Date Title
KR950016732A (ko) 피부 및 질의 위축 억제방법
KR950016744A (ko) 트롬빈을 저해하는 방법
KR950016738A (ko) 알쯔하이머 질병의 억제 방법
KR950016746A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR950016725A (ko) 폐 고혈압성 질병을 억제하는 방법
KR970706818A (ko) 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide)
KR950016731A (ko) 지루 및 좌창의 억제 방법
KR950010893A (ko) 자궁내막증 억제 방법
KR950010892A (ko) 자궁 섬유증 억제 방법
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
KR950016723A (ko) 자가면역 질병의 억제 방법
RU97108050A (ru) Способ ингибирования состояний, связанных с нейропептидом y
KR950010890A (ko) 폐경기 증후군의 치료방법
KR950016726A (ko) 기능부전성 자궁 출혈을 억제하는 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
KR950016730A (ko) 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법
KR950016740A (ko) 조직의 불완전한 회복을 저해하는 방법
KR950016734A (ko) 성적 조숙증의 억제방법
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
KR950010891A (ko) 내성 종양을 치료하는 방법
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR950010887A (ko) 연골 퇴화 억제 방법
KR950016742A (ko) 폐경후 여성의 씨엔에스 질환을 억제하는 방법
KR950016735A (ko) 터너 증후군의 억제 방법
KR950016729A (ko) 유방 질환의 억제 방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid